$BCAB News
Last published 5mo ago
- 5mo agoBCABCNTXContext Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202GlobeNewswireContext announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 PHILADELPHIA, May 18,
- 7mo agoBCABBioAtla Announces Share ConsolidationGlobeNewswireSAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 7mo agoBCABBioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsGlobeNewswireInitiated a formal process to monetize assets Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a
- 8mo agoBCABBioAtla Announces Formal Process to Evaluate Strategic Options to Monetize AssetsGlobeNewswireSAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 10mo agoBCABBioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)GlobeNewswireBioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.BioAtla to retain 65%
- 11mo agoBCABBioAtla Enters into Agreements for up to $22.5 Million Flexible FinancingGlobeNewswireThese agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnershipCompany is in advanced stages to finalize a strategic transaction with a potential partner,
- 12mo agoBCABBioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent ProgressGlobeNewswireCompany achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approvalCompany is in
- 1y agoBCABBioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue SarcomasGlobeNewswire— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents —
- 1y agoBCABBioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025GlobeNewswireSAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 1y agoBCABBioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus SocietyGlobeNewswireSAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 1y agoBCABBioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025GlobeNewswireAdverse events (AEs) generally transient and readily manageable; only 2 cases of cytokine release syndrome (CRS)Prolonged tumor control with increasing doses of BA3182; confirmed partial response (cPR) at 0.6 mg in a
- 1y agoBCABBioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025GlobeNewswireSAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its
- 1y agoBCABBioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDAGlobeNewswireFDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approvalCompany continues preparations for enabling initiation of the Phase 3
- 1y agoBCABBioAtla, Inc. (BCAB) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoBCABBioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent ProgressGlobeNewswireCAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin
- 1y agoBCABBioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025GlobeNewswireSAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 1y agoBCABBioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia MeetingGlobeNewswireSAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB) (the "Company" or "BioAtla"), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB)
- 1y agoBCABBioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers CongressGlobeNewswireAdverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients Dose escalation now
- 1y agoBCABBioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimenGlobeNewswire45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior lines of therapy Marked unmet need exists in 2L+ HPV+ OPSCC patients; standard of care agents
- 1y agoBCABBioAtla Reports First Quarter 2025 Financial Results and Highlights Recent ProgressGlobeNewswireCAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin
- 1y agoBCABBioAtla to Participate in the Citizens Life Sciences ConferenceGlobeNewswireSAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 1y agoBCABBioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025GlobeNewswireSAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 1y agoBCABBioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswireSAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 1y agoBCABBioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireSAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 1y agoBCABBioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent ProgressGlobeNewswireCAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated
- 1y agoBCABBioAtla Announces Two Poster Presentations at Upcoming Medical MeetingsGlobeNewswireSAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 1y agoBCABBioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025GlobeNewswireSAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 1y agoBCABBioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection PointsGlobeNewswireSAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company ("BioAtla" or the "Company") focused on the development of Conditionally Active Biologic (CAB)
- 1y agoBCABBioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science MeetingGlobeNewswireImproved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory
- 1y agoBCABBioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science MeetingGlobeNewswireSAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 2y agoBCABBioAtla, Inc. (BCAB) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoBCABBioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent ProgressGlobeNewswireOzuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical responses and median overall survival (OS) of approximately 9 months
- 2y agoBCABBioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024GlobeNewswireSAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 2y agoBCABBioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual MeetingGlobeNewswireSAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 2y agoBCABBioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International CongressGlobeNewswireSAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 2y agoBCABCNTXBioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging AntibodyGlobeNewswireContext to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones
- 2y agoBCABBioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual MeetingGlobeNewswireAn ongoing complete response (CR) with an overall response rate (ORR) of 32% achieved across two dosing regimens Underscores ozuriftamab vedotin's activity in a high unmet need SCCHN patient population The
- 2y agoBCABBioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual MeetingGlobeNewswireSAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 2y agoBCABBioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireSAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 2y agoBCABBioAtla, Inc. (BCAB) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoBCABBioatla Reports Second Quarter 2024 Financial Results and Highlights Recent ProgressGlobeNewswireOzuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track Designation by FDA in squamous cell carcinoma of the head and neck (SCCHN); anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024Evalstotug
- 2y agoBCABBioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024GlobeNewswireSAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 2y agoBCABBioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D DayGlobeNewswireClinical benefit observed among non-small cell lung cancer (NSCLC) patients harboring mutant KRAS (mKRAS) variants in the Phase 2 mecbotamab vedotin (CAB-AXL-ADC) study; AXL tumoral expression highly associated with
- 2y agoBCABBioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckGlobeNewswireOzuriftamab vedotin, the Company's conditionally and reversibly active antibody drug conjugate directed against ROR2, has shown promising clinical activity with a manageable safety profile in treatment-refractory
- 2y agoBCABBioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024GlobeNewswireSAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 2y agoBCABBioAtla to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswireSAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
- 2y agoBCABBioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireMultiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug High doses of evalstotug as either a
- 2y agoBCABBioAtla, Inc. (BCAB) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoBCABBioAtla Reports First Quarter 2024 Financial Results and Highlights Recent ProgressGlobeNewswireOzuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for SCCHN potential
- 2y agoBCABBioAtla to Participate in the Citizens JMP Life Sciences ConferenceGlobeNewswireSAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the